Kendall South Medical Center, Inc.

Miami, Florida 33185-5948

3 studies enrolling now · 25 studies all time

What they study most

ASCVD, Arthritis, Atherosclerotic Cardiovascular Disease, COVID 19 Disease, COVID-19, Cardiovascular Disease, Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Dyslipidemia, Dyslipidemias, Familial Hypercholesterolemia, Gout

Studies at this site

• A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts — Recruiting now
• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes — Recruiting now
• A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease — Starting soon
• A Study of S-892216 in Participants With COVID-19 — Completed
• Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies — Completed
• Tafenoquine in Patients With Mild to Moderate COVID-19 — Completed
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). — Stopped early
• Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease — Stopped early
• A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection — Completed
• A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function — Completed
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures — Completed
• Tanezumab in Osteoarthritis of the Hip or Knee (2) — Completed
• Tanezumab In Osteoarthritis Of The Knee (2) — Completed
• Extension Study Of Tanezumab In Osteoarthritis — Stopped early
• Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain — Completed
• Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL) — Completed
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin — Completed
• A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins — Completed
• Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception — Completed
• Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder — Completed
• Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder — Completed